Filtered By:
Condition: Metabolic Syndrome

This page shows you your search results in order of date.

Order by Relevance | Date

Total 67 results found since Jan 2013.

GSE222499 Liver-specific FGFR4 knockdown in mice on a HFD increases bile acid synthesis and improves hepatic steatosis II
Contributor : Softic SamirSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusNonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease with increased risk in patients with metabolic syndrome. There are no FDA approved treatments, but farnesoid X receptor (FXR) agonists have shown promising results in clinical studies for NAFLD management. In addition to FXR,  fibroblast growth factor receptor FGFR4 is a key mediator of hepatic bile acid synthesis. Using N-acetylgalactosamine-conjugated siRNA, we knocked down FGFR4 specifically in the liver of mice on chow or...
Source: GEO: Gene Expression Omnibus - January 11, 2023 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research

Elimination of fibrin polymer formation or crosslinking, but not fibrinogen deficiency, is protective against diet-induced obesity and associated pathologies
CONCLUSIONS: Consistent with prior studies, Fib𝛾390-396A mice were significantly protected from increased adiposity, NAFLD, hypercholesterolemia and diabetes while Fib- and siFga-treated mice gained as much weight and developed obesity-associated pathologies identical to wildtype mice. FibAEK and FXIII- mice displayed an intermediate phenotype with partial protection from some obesity-associated pathologies. Results here indicate that fibrin(ogen) lacking αM β2 binding function offers substantial protection from obesity and associated disease that is partially recapitulated by preventing fibrin polymer formation or cr...
Source: Thrombosis and Haemostasis - September 16, 2022 Category: Hematology Authors: Woosuk S Hur Katharine C King Yesha N Patel Y-Van Nguyen Zimu Wei Yi Yang Lih Jiin Juang Jerry Leung Christian J Kastrup Alisa S Wolberg James P Luyendyk Matthew J Flick Source Type: research

Treatment of the metabolic syndrome by siRNA targeting apolipoprotein CIII
AbstractApolipoprotein CIII (apoCIII) is increased in obesity-induced insulin resistance and type-2 diabetes. Emerging evidences support the advantages of small interfering RNAs (siRNAs) to target disease-causing genes. The aim of this study was to develop siRNAs for in vivo silencing of apoCIII and investigate if this results in metabolic improvements comparable to what we have seen using antisense oligonucelotides against apoCIII. Twenty-four siRNAs were synthesized and tested in a dual luciferase reporter assay. The eight best were selected, based on knockdown at 20  nM, and of these, two were selected based on IC50 v...
Source: BioFactors - September 1, 2022 Category: Biochemistry Authors: Patricia Recio ‐López, Ismael Valladolid‐Acebes, Philipp Hadwiger, Markus Hossbach, Monika Krampert, Carla Prata, Per‐Olof Berggren, Lisa Juntti‐Berggren Tags: RESEARCH COMMUNICATION Source Type: research

Abstracts of Presentations at the Association of Clinical Scientists 143 < sup > rd < /sup > Meeting Louisville, KY May 11-14,2022
Conclusion: These assays are suitable for routine diagnostic. The UltraFast NextGenPCR is the fastest with average time (30mins), followed by Agilent (2 hrs) and MassArray (6hrs). Upon completion of this activity, participants should be able to examine, measure and compare results from different assays for SARS detection, evaluate and diagnose accurately, as well as being able to plan, organize and recommend a diagnostic procedure for diagnostic laboratory. Key words: SARS-CoV-2, RNA extraction, RT-PCR, limit of detection, quantification cycle, COVID-19, in vitro diagnostic tests, Agilent, Massarray, Ultrafast. [20] From t...
Source: Annals of Clinical and Laboratory Science - July 1, 2022 Category: Laboratory Medicine Source Type: research